New Data to be Presented at the European Academy of Neurology (EAN) Congress 2015 Highlights Eisai's Commitment to Its Leading Epilepsy Portfolio

HATFIELD, England, June 18, 2015 /PRNewswire/ --

PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR SWISS/AUSTRIAN/US JOURNALISTS 

Eisai is proud to present key data from its epilepsy portfolio, the largest of its kind in the Europe, at the first European Academy of Neurology Congress (EAN) in Berlin, Germany. Eisai presents data on the efficacy of adjunctive Fycompa^® (perampanel) in idiopathic generalised epilepsy via oral and poster presentations.

"Epilepsy is a challenging condition to manage, it is therefore important that we strive to find effective treatments to support people with epilepsy. These new data at EAN 2015 reinforce Eisai's investment in new epilepsy treatment options with the potential to improve outcomes in different patient populations," comments Neil West, Vice President, Global Neurology Business Unit, Eisai EMEA.

The following abstracts are accepted for presentation at the EAN congress:

   
    Abstract Number           Abstract details
    Perampanel


    Abstract number: #1362    Efficacy of adjunctive perampanel in idiopathic
    Monday 22 June            generalised epilepsy: Subgroup analysis of patients with
    12:30-13:15               absence and myoclonic seizures in a double-blind
    Screen B1, P3139          placebo-controlled Phase 3 trial
                              Terence J O'Brien, Bernhard J Steinhoff, Haichen Yang,
                              Antonio Laurenza, Anna Patten, Francesco Bibbiani

    Abstract number: #393     Efficacy of adjunctive perampanel in idiopathic
    Sunday 21 June            generalised epilepsy patients with drug-resistant primary
    14:14-16:15               generalised tonic-clonic seizures by age, sex, race:
    Hall A2, O2112            Double-blind PBO-controlled Phase 3 trial
                              Bernhard J Steinhoff, Terence J O'Brien, Haichen Yang,
                              Antonio Laurenza, Anna Patten, Francesco Bibbiani

The continued development of its epilepsy portfolio underscores Eisai's human health care (hhc) mission, the company's commitment to innovative solutions in disease prevention, cure and care for the health and wellbeing of people worldwide. Eisai is committed to the therapeutic area of epilepsy and to address the unmet medical needs of people with epilepsy and their families. Eisai is proud to currently market more epilepsy products in EMEA than any other company.

Notes to Editors 

About Fycompa^® (perampanel) 

Perampanel is indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.^[1]

Perampanel is a highly selective, non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)-type glutamate receptor antagonist that has demonstrated seizure reduction in Phase II and III studies. AMPA receptors, widely present in almost all excitatory neurons, transmit signals stimulated by the excitatory neurotransmitter glutamate within the brain and are believed to play a role in central nervous system diseases characterised by excess neuroexcitatory signalling including epilepsy.^[1]

For further information please visit: http://www.fycompa.eu  

About Epilepsy  

Epilepsy is one of the most common neurological conditions in the world, affecting approximately 6 million people in Europe, and an estimated 50 million people worldwide.^[1],[2] Epilepsy is a chronic disorder of the brain that affects people of all ages. It is characterised by abnormal discharges of neuronal activity which causes seizures. Seizures can vary in severity, from brief lapses of attention or jerking of muscles, to severe and prolonged convulsions. Depending on the seizure type, seizures may be limited to one part of the body, or may involve the whole body. Seizures can also vary in frequency from less than one per year, to several per day. Epilepsy has many possible causes but often the cause is unknown.

About Eisai EMEA in Epilepsy  

Eisai is committed to developing and delivering highly beneficial new treatments to help improve the lives of people with epilepsy. The development of AEDs is a major strategic area for Eisai in Europe, the Middle East, Africa, Russia and Oceania (EMEA).

In the EMEA region, Eisai currently has four marketed treatments including:

• Fycompa^® (perampanel) for the adjunctive treatment for partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older
• Zebinix^® (eslicarbazepine acetate) as adjunctive therapy in adults with partial onset seizures, with or without secondary generalisation (Zebinix is under license from BIAL)
• Zonegran^® (zonisamide) as monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy and as adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above (Zonegran is under license from the originator Dainippon Sumitomo Pharma)
• Inovelon^® (rufinamide) for the adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients four years of age and older (Rufinamide was originally developed by Novartis)

About Eisai Co Ltd 

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realise our hhc philosophy by delivering innovative products in multiple therapeutic areas with high unmet medical needs, including oncology and neurology. 

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit http://www.eisai.com.

References 

1. Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe. http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510.pdf (Accessed June 2015) 

2. Pugliatti M et al. Estimating the cost of epilepsy in Europe: A review with economic modeling. Epilepsia 2007:48(12):2224-33 

Date of preparation: June 2015 

Job code: Perampanel-UK2192